Co-Chairs:

  • Ramya Ramaswami, HIV and AIDS Malignancy Branch, Center for Cancer Research (CCR), National Cancer Institute, Bethesda, USA
  • Alessia Dalla Pria, Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK; Centre for Immunology and Vaccinology, Department of Infectious Diseases, Imperial College, London, UK

Presenters & Panelists:

  • David Boutboul, Clinical Immunology Department, INSERM U976 HIPI, Hôpital Saint Louis, Paris
  • Kathryn Lurain, The Ohio State University, Comprehensive Cancer Center, Department of Internal Medicine, Division of Hematology, Columbus, USA

Despite substantial advances in KSHV virology, connecting mechanistic insights to the clinical manifestations of KSHV-associated disease remains a major challenge. The clinical landscape has evolved rapidly, with increasingly heterogeneous presentations across immunocompromised and immunocompetent hosts. Translating advances in viral and host biology into meaningful improvements in diagnosis, risk stratification, and therapy remains an unmet need. This session will highlight how current clinical gaps intersect with unanswered questions in virus–host interactions, leading us to identify opportunities for translational research with direct relevance to patient care.